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A 37-year-old white woman was referred to the Cleveland Clinic
Foundation for evaluation of a right suprarenal mass. BeginningS years
before, she had experienced episodes of severe headache, pounding
heart, and flushing, followed by facial pallor and tremulousness. Nei-
ther blood pressure nor heart rate was checked during these spells. The
attacks occurred about twice monthly and lasted for 5 to 20 minutes.
She noted that "bearing down" during defecation or "curling up" on
her left side often precipitated these episodes.
She consulted 6 physicians over the subsequent 4 years; no diagnosis
was made to explain her symptoms. One year ago, she consulted a
neurologist, who performed a thorough examination and obtained a
magnetic resonance image of the head: no abnormalities were detected.
One month before she came to the Cleveland Clinic, her private
physician obtained an abdominal sonogram because he suspected an
abdominal aneurysm. The study revealed a "5.2 x 5.1 cm solid,
hyperechoic suprarenal mass" on the right side. Neither she or her
family had a significant medical history.
Physical examination revealed a blood pressure of 122/76 mm Hg:
pulse, 80 beats/mm and regular: and respiratory rate, 16/mm. The rest
of the examination was unremarkable.
Laboratory studies revealed: normal SMA-l6 values except for a
blood glucose of 133 mg/dl: normal thyroid function: serum calcium. 8.8
mg/dl; plasma norepinephrine. 1456 pg/mI: epinephrine. 259 pg/mI;
24-hr urinary metanephrine, 5728 g/24 hr: normetanephrine, 10,465
g/24 hr; and serum chromogranin A, 162 ng/ml (normal. 50 ng/ml).
An abdominal CT scan revealed a right suprarenal mass measuring
about 6.0 cm diameter, which demonstrated a high signal intensity on
the T2-weighted image by MRI (Fig. I). The mass concentrated high
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amounts of radioiodinated metaiodobenzylguanidine ('311-M1BG) 72
hours after intravenous administration of the radioisotope (Fig, 2).
A right adrenal mass was excised without incident. The mass weighed
95 g and measured 6.0 x 5.3 >< 4.4 cm. The cut surface was variegated,
and focal hemorrhagic areas were scattered throughout. A large cystic
area measured 1.6 cm in diameter. Histologic examination was com-
patible with pheochromocytoma.
Discussion
DR. EMMANUEL L. BRAVO (Head, Endocrine/Hypertension
Research Laboratort', Department of Heart and Hypertension,
Research Institute, Cleveland Clinic Foundation, Cleveland,
Ohio): This case exemplifies the patient with a pheochromocy-
toma who remained undiagnosed for years. Diagnosing this
condition early is very important because removal of the tumor
results in cure in approximately 90% of patients but, if left
untreated, pheochromocytoma can be lethal. The principal
focus of my discussion will be on non-malignant pheochromo-
cytomas, which account for more than 90% of all such tumors.
I will discuss malignant pheochromocytomas briefly near the
end of this Forum.
The diagnosis of pheochromocytonia is not difficult to make
when the patient presents with classic manifestations of the
disease, or when an increase in catecholamine production is
clear-cut. When the patient presents with uncommon symptoms
and equivocal biochemical tests, however, the disease provides
a diagnostic challenge. In this setting, a carefully planned
sequence of studies including appropriate biochemical testing
and localizing techniques is required to substantiate the diag-
nosis of pheochromocytoma.
Clinical manifestations
Pheochromocytomas can cause a wide variety of symptoms.
The most common set of findings comprises attacks of head-
ache, sweating, and tachycardia [I]. In one study, the sympto-
matic triad of headache, sweating attacks, and tachycardia in a
hypertensive patient was found to have a specificity of 93.8%
and a sensitivity of 90.9% in the diagnosis of pheochromocy-
toma [2]. Palpitations, anxiety, and tremulousness are common
when the tumor produces a large amount of epinephrine; these
symptoms are present only in approximately 50% of patients,
however. Hypertension, the most common feature, occurs in
more than 90% of patients and is paroxysmal in 25% to 50% of
patients [3].
in a patient with a pheochromocytoma, endocrine abnormal-
ities can dominate the clinical picture. Hypercalcemia can be
related to excessive production by the pheochromocytoma of
parathyroid hormone [41; diarrhea can result from increased
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Fig. 1. Localization of pheochromocytoma by
abdominal CT scan (left) and by MRI (right, T2
weighted image.) (From case presentation.)
Fig. 2. Localization of pheochromoc toma employing '311-MIBG. Up-
take of '31l-MIBG by the same tumor shown in Fig. 1, 72 hours after
radioisotope injection. (From case presentation.)
production of vasoactive intestinal peptide [5, 61; and cushin-
goid features, accompanied by severe hypokalemic alkalosis,
can arise from overproduction of ACTH [7—9].
Some patients present with an acute surgical abdomen due to
bowel ischemia and/or hemorrhagic necrosis of the tumor
[10—14]. Others present with constant abdominal pain associ-
ated with marked hypertension followed by hypotension and
even shock and sudden death [13, 14]. Sudden death probably
results from marked arterial and venous dilation due to sudden
withdrawal of catecholamines, the hypotension being com-
pounded by the presence of intravascular hypovolemia.
Overt diabetes can occur in patients with pheochromocytoma
because catecholamines antagonize insulin release [15]. Lactic
acidosis in the absence of shock should arouse suspicion of
pheochromocytoma [16]. The increase in lactate production is
thought to reflect a direct stimulation by epinephrine associated
with decreases in oxygen delivery and increases in oxygen
utilization.
Cardiovascular abnormalities occur commonly in patients
with pheochromocytomas, the commonest probably being my-
ocarditis [171. Patients often present with signs and symptoms
like those observed in acute myocardial infarction [18]. Cardiac
arrhythmias, including atrial and ventricular fibrillation, can be
precipitated by anesthetic agents or surgery for unrelated
conditions. These arrhythmias probably are due to the sudden
release of catecholamines. Dilated congestive cardiomyopathy,
believed to be related to myocarditis, has been described in
some patients [17]. Pulmonary edema, which can be either
cardiogenic or noncardiogenic in origin, can be the first mani-
festation of a pheochromocytoma. Noncardiogenic pulmonary
edema is believed to result from transient increases in pulmo-
nary capillary pressure due to pulmonary venoconstriction and
increased pulmonary capillary permeability [19, 20].
Altered mental status, focal neurologic signs and symptoms,
and/or seizures occasionally are observed during a hypertensive
crisis [I]. Stroke due to cerebral infarction, intracerebral hem-
orrhage resulting from severe arterial hypertension, and/or
emboli secondary to mural thrombus from a dilated cardiomy-
opathy also can complicate pheochromocytoma. Finally, cer-
tain drugs sometimes precipitate a hypertensive crisis in pa-
tients harboring a pheochromocytoma. Such drugs include
tricyclic antidepressants [21]. antidopaminergic agents (for ex-
ample, sulpiride) and metoclopramide [221, and naloxone [23].
Unrelated disorders are likely to be confused with pheochro-
mocytoma on the basis of catecholamine levels (Table 1).
Angina pectoris, acute clonidine withdrawal, hypoglycemia,
and vasodilator therapy (with either minoxidil or hydralazine)
can produce plasma catecholamine values as high as those
observed in pheochromocytoma [24].
The fact that pheochromocytomas can present in many ways
explains why so many of these tumors are missed. In a series
from the Mayo Clinic, 41 of the 54 autopsy-proven cases were
unsuspected clinically during life [25]. Of the 13 (of the 54 cases)
correctly diagnosed before death, 4 cases were discovered
incidentally at laparotomy for unrelated conditions. Of those
diagnosed after death, only 54% had had hypertension. Head-
aches (27%), diaphoresis (17%), and palpitations (17%) were
much less common than in patients whose tumor was diagnosed
before death. Twelve patients were older than 68 years; in 9 of
these elderly patients, the diagnosis was unsuspected. In a
retrospective study from Australia. 29 of 46 proven cases were
diagnosed and treated during life, whereas 17 were diagnosed at
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Table 1. Clinical syndromes likely to be confused with
pheochromocytomaa
/3-Adrenergic hyperresponsiveness
Angina pectoris
Acute infection
Autonomic epilepsy
Hyperthyroidism
Idiopathic orthostatic hypotension
Cerebellopontine angle tumors
Acute hypoglycemia
Tyramine ingestion in patients receiving MAO inhibitorst
Menopausal syndrome with migraine headaches
Acute drug withdrawal
Clonidine
/3-Adrenergic blockade
a-Methyldopa
Vasodilator therapy
Hydralazine
Minoxidil
Factitious administration of sympathomimetic agents
a From Ref. 24.
b MAO = monoamine oxidase.
autopsy [26]. Of the latter, 14 died of cardiovascular complica-
tions that were attributed to their disease. Most of the tumors
discovered at autopsy were found in patients 60 years or older.
Stenstrom and Svardsudd reviewed their experience in 439
patients with pheochromocytoma registered in Sweden from
1958 to 1981 127]. The incidence of pheochromocytoma in-
creased continously with advancing age both for men and
women. In 184 cases (40%) the diagnosis was made at autopsy.
Pheochromocytoma was an incidental finding in 60(14% of all
cases). The average age at diagnosis in those whose disease was
discovered before death was 48.5 years, significantly lower than
the average age at death in those diagnosed only at autopsy,
which was 65.8 years. Similarly, Krane found that of 32 patients
with pathologically confirmed tumors, II patients had tumors
that were clinically unsuspected [281. Of these 11, 9 patients
were considered asymptomatic during their lifetimes.
These observations indicate that a high percentage of patients
with pheochromocytoma present with minor or no signs and
symptoms. Further, elderly patients appear to present a special
diagnostic challenge. A contributory factor to the rarity of the
antemortem diagnosis of pheochromocytoma in the elderly may
be a decrease in sensitivity to catecholamines with age. Addi-
tionally, most elderly patients have concomitant disease, the
signs and symptoms of which can confound the diagnosis.
Cardiac and neurologic symptoms often are attributed to coro-
nary artery and cerebrovascular disease from atherosclerosis.
New concepts in pathophysiology
At first blush, the mechanism of elevated blood pressure in
patients with pheochromocytoma might seem to be the most
straightforward of all the secondary forms of hypertension.
Surprisingly, however, approximately 15% of patients are nor-
motensive [29]. In addition, no relationship exists between the
prevailing levels of plasma catecholamines and the height of
arterial blood pressure (Fig. 3)130]. Indeed, normotension in
the presence of increased circulating catecholamines is not
uncommon.
Several factors can alter the response of the vascular smooth
muscle to circulating catecholamines. One factor is blood
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Fig. 3. Relationship between the height of arterial blood pressure and
the level of circulating plasma catecholamines in pheochromocytoma.
The horizontal line refers to the upper limits of MAP (i.e., 106mm Hg);
the vertical axis refers to the upper limit of 99% confidence intervals of
plasma catecholamines (NE + E) in normals. (From Ref. 30.)
volume. Hypovolemia diminishes the blood pressure response
to circulating pressor agents. Hypovolemia is not a universal
finding in this disorder, however [31], and occurs in only
approximately 50% of patients. In addition, blood volume is
inversely related to the height of diastolic blood pressure; this
relationship would be direct if the height of arterial blood
pressure depended solely on the level of intravascular volume.
Prolonged stimulation of a tissue by adrenergic agonists can
diminish responsiveness of the tissue to subsequent activation
by catecholamines; this phenomenon has been termed desensi-
tization, or tachyphylaxis. Tsujimoto and colleagues examined
the in-vivo consequences of prolonged stimulation of vascular
alpha-adrenergic receptors in rats harboring norepinephrine-
producing tumors [321. In the early stages of the disease,
sensitivity was lost for both al- and a2-adrenergic agonists,
whereas responsiveness to arginine vasopressin and angioten-
sion II was intact. Additionally, radioligand binding studies
showed that the number of crl-adrenergic receptors decreased
by 36% in mesenteric artery plasma membrane from these rats,
whereas the number of s2-adrenergic receptors was unaltered.
These results provide a plausible explanation for the observa-
tion that patients can be normotensive or only moderately
hypertensive despite high circulating levels of catecholamines.
It has always been assumed that sympathetic nerve activity in
patients with pheochromocytoma would be depressed because
of the high circulating catecholamines. However, both clinical
and experimental evidence suggests that the sympathetic ner-
vous system plays a significant role in the maintenance of
hypertension in patients with pheochromocytoma. The clinical
evidence for this conclusion comes from our studies of the
effects of orally administered clonidine in patients with either
essential hypertension or pheochromocytoma [33]. Clonidine, a
centrally acting cr2-agonist, inhibits neurally mediated catechol-
amine release. Clonidine decreases blood pressure to the same
degree in patients with pheochromocytoma as it does in those
with essential hypertension. These results suggest that the
sympathetic nervous system is intact in pheochromocytoma. In
essential hypertension, the fall in blood pressure is associated
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with decreases in circulating catecholamines, but in pheochro-
mocytoma, plasma catecholamine levels do not change [331.
The discrepancy between the fall in blood pressure in patients
with pheochromocytoma after clonidine administration and the
persistently high levels of circulating catecholamines suggests
that the norepinephrine released from axon terminals of sym-
pathetic postganglionic neurons is biologically more significant
than circulating catecholamines. This discrepancy could be
related to the easier access of norepinephrine released from
postganglionic neurons to its site of action at effector cells.
Neural control of blood pressure also exists in rats implanted
with a pheochromocytoma. Eliminating sympathetic nerve ac-
tivity by pithing caused a greater reduction of blood pressure in
pheochromocytoma-bearing rats than in age-matched, unim-
planted rats [32]. Additionally, Prokocimer and coworkers
found that both clonidine and chlorisondamine (a ganglion
blocker) markedly decreased blood pressure in intact rats with
pheochromocytoma [34]. However, the observation that the
blood pressure in pithed rats with pheochromocytoma is further
reduced by phentolamine, an alpha-adrenergic antagonist, sug-
gests that high concentrations of circulating catecholamines
also are involved in the maintenance of the elevated blood
pressure. Thus, the hypertension in pheochromocytoma is a
complex process influenced by the sympathetic nervous sys-
tem, by circulating catecholamines, and by alterations in car-
diovascular responses to catecholamines.
Our studies of the hemodynamics of hypertension reveal that
despite having tenfold higher levels of circulating catechol-
amines, patients with pheochrornocytoma have hemodynamic
characteristics similar to those in patients with essential hyper-
tension [35]. In both groups, increased total peripheral resis-
tance is primarily responsible for maintenance of hypertension.
These results further support the concept that the sympathetic
nervous system regulates blood pressure in both groups of
patients.
Orthostatic hypotension occurs in about 40% of patients with
pheochromocytoma and probably is caused by a combination of
hypovolemia and impaired venous and arterial constrictor re-
flex responses. However, blood volume does not differ between
patients who exhibit postural hypotension and those who do
not. In patients who develop significant blood pressure reduc-
tions on standing, the most consistent hemodynamic changes
were decreases in systolic arterial pressure (without changes in
diastolic blood pressure) and decreases in cardiac output with-
out any compensatory increase in total peripheral resistance
[361. These observations suggest impaired vascular reflexes, but
it is unclear why some patients have this hemodynamic abnor-
mality and some do not.
Experimental studies suggest that catecholamines increase
protein synthesis and might play a role in cardiac hypertrophy
[37]. However, patients with pheochromocytoma had left-
ventricular-mass indices similar to those in patients with age-
and sex-matched essential hypertension who had tenfold lower
plasma catecholamine values [38].
Evaluationfor suspected pheochromocytoma
Priority for evaluation for the presence of pheochromocy-
toma should be given to patients with any of the following: (I)
the triad of episodic headaches, tachycardia, and diaphoresis
(with or without associated hypertension); (2) family history of
pheochromocytoma; (3) signs or symptoms indicating a multi-
ple endocrine adenoma (MEA) syndrome; (4) "incidental"
suprarenal masses; (5) hypertension associated with equivocal
increases in catecholamine production; and (6) adverse cardio-
vascular manifestations in response to anesthesia, to any sur-
gical procedure, or to certain medications known to precipitate
symptoms in patients with pheochromocytoma.
Biochemical tests. The most useful urine tests measure
concentrations of metanephrine, vanillylmandelic acid (VMA),
and free (unconjugated) catecholamirtes. These tests have been
compared in patients with confirmed pheochromocytoma and in
hypertensive patients without the tumor. In 43 patients with
tumors, the false-negative rates were 30% for urinary VMA and
10% for urinary metanephrines [39]. In another study, none of
25 patients with pheochromocytoma had a false-negative rate
for urinary free norepinephrine [401. Thus, assays of 24-hour
urinary catecholamines and metanephrines are adequate for
diagnosing pheochromocytoma in most patients.
Sole reliance on determination of urinary catecholamine
metabolites as indices of catecholamine production can be
misleading, however. The amounts and types of metabolites
excreted in urine depend on a number of factors. First, the
handling of catecholamines by the kidney depends on both
degradation and excretion [41]. Second, in patients with pheo-
chromocytoma, the activities of the enzymes involved in cate-
cholamine synthesis (tyrosine hydroxylase, aromatic amino
acid decarboxylase, and dopamine 13-hydroxylase) are mark-
edly increased, whereas the activities of the enzymes involved
in catecholamine catabolism (monoamine oxidase and catechol-
o-methyltransferase) are reduced [42]. Thus, excess amounts of
newly synthesized norepinephrine that cannot be stored in the
filled catecholamine storage vesicles are not always degraded,
and the norepinephrine diffuses from the pheochromocytoma
into the circulation. This efflux could result in large amounts of
circulating norepinephrine with relatively small increases in
urinary catecholamine metabolites. Third, the size of the tumor
is an important determinant of the relative amounts of catechol-
amine excretory products. Crout and Sjoerdsma demonstrated
that tumors weighing less than 50 g have rapid turnover rates
and release mainly unmetabolized catecholamines into the
circulation, producing low concentrations of metabolites rela-
tive to free catecholamines in the urine [43]. On the other hand,
tumors weighing more than 50 g have slow turnover rates and
release mainly metabolized catecholamines into the circulation,
resulting in high concentrations of inetabolites relative to free
catecholamines in the urine. These observations have important
clinical implications. Because small tumors release free unme-
tabolized catecholamines into the circulation, they tend to
produce more symptoms and are best diagnosed by the mea-
surement of plasma catecholamines. In contrast, patients who
have large tumors that metabolize most of the secreted cate-
cholamines exhibit few symptoms and have relatively lower
circulating free catecholamines but high urinary excretions of
catecholamine metabolites.
Figures 4 and 5 depict plasma catecholamine levels in a group
of patients with pheochromocytoma; these values are compared
with those from patients with essential hypertension [44]. It is
clear that the majority of patients with pheochromocytoma
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Fig. 4. Plasma norepinephrine ralues in adrenal and extra-adrenal
pheochrornocytoma. The cross-hatched area represents the mean (425
pg/mi) and the 95% confidence limits (upper limit, 811 pg/mi) of values
obtained from 104 patients with essential hypertension. (From Bravo
EL: Adrenal medullary function, in Diagnostic Endocrinology, edited
by MOORE WT, EASTMAN RC, Philadelphia. BC Decker, 1990, p 220.)
have elevated plasma catecholamine levels that markedly ex-
ceed those in patients with essential hypertension. Three pa-
tients had plasma norepinephrine values that fell within the 95%
confidence limits for values obtained in patients with essential
hypertension (that is, below 811 pg/mI). None had values that
fell within the range for sex- and age-matched normotensive
subjects (that is, below 402 pg/mI). It is evident that the plasma
epinephrine concentration has little value in predicting the
location of a tumor. Although some patients with adrenal
pheochromocytomas have plasma epinephrine values within
the normal range, some patients with extra-adrenal tumors have
values distinctly above the normal range. In practice, plasma
catecholamine values (the sum of norepinephrine and epineph-
rifle) that exceed 2000 pg/mI are considered abnormal, and
values less than 500 pg/mI are normal: values between 500 and
2000 pg/mI are equivocal, should be repeated, and require
confirmation by measurement of 24-hour urinary catecholamine
metabolites and/or pharmacologic testing.
Figure 6 compares simultaneously measured plasma cate-
cholamines, urinary metanephrine, and VMA in patients with
pheochromocytoma 1391. Using measurements in patients with
essential hypertension as reference values, we found false-
negative results for urinary VMA in 25 of the 43 patients. On the
other hand, only 9 had false-negative results for urinary meta-
nephrine. In one patient, all three biochemical measurements
were within the ranges seen in essential hypertension. In
another patient, an elevated level of urinary metanephrine was
the only biochemical abnormality, and in 3 patients, the only
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Fig. 5. Plasma epinephrine moInes in adrenal and extra—adrenal plieo—
cliromnocvtona The cross-hatched area represents the mean (59 pg/mI)
and the 95% confidence limits (upper limit, 145 pg/mI) of values
obtained from 104 patients with essential hypertension. (From Bravo
EL: Adrenal medullary function, in Diagnostic Endocrinology, edited
by MOORE WI, EASTMAN RC, Philadelphia, BC Decker, 1990, p 221.)
abnormal result was an elevated plasma catecholamine level.
These findings are in accord with the demonstration of variable
metabolism and degradation of catecholamines in pheochromo-
cytomas. Further, these results suggest that of the urinary
catecholamine metabolites, urinary metanephrine provides a
more reliable clue to the presence of pheochromocytoma than
does urinary VMA, and that plasma catecholamine measure-
ments are at least as reliable as is measurement of urinary
metanephrine in predicting the presence of pheochromocy-
toma.
Catecholamine values in normotensive and hypertensive sub-
jects are shown in Table 2. The sensitivity and specificity of the
various biochemical tests appear in Table 3. Measurement of
plasma catecholamines seems to have the highest sensitivity
and specificity; the measurement of urinary VMA has the
lowest. All three tests provide excellent positive predictive
value when values are elevated, however.
The availability of tests in any given center necessarily
determines the nature of the investigation in an individual
patient, and debate over the relative merits of various tests will
continue. However, it seems likely that for 100% diagnostic
accuracy, multiple tests may have to be performed taking into
account the limitations and pitfalls of some analytical methods.
Because the metabolism of catecholamines in patients with
pheochromocytoma may be modified by either a lack or an
excess of metabolizing enzymes, plasma catecholamines as well
as catecholamine metabolites in urine (preferably metaneph-
rine) should be measured in equivocal cases.
Plasma chromogranin A concentration has been proposed as
a diagnostic test for pheochromocytoma: plasma levels are
about tenfold higher than those in other hypertensive patients
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Table 2. Catecholamine values in normotensive and hypertensive
patients with proven pheochromocytoma'
Normotensive Hypertensive
Biochemical subjects subjects
—
measurements (n = 40) (n = 70)
Plasma norepinephrine 218 92 pglm!b 425 193 pg/ml'
Plasma epinephrine 42 18 pg/mlt 59 38 pg/mlh
Urinary VMAC <6.8 mg/24 hr <11.0 mg/24 hr
Urinary NMN + MNC <1.3 mg/24 hr <1.8 mg/24 hr
Urinary_norepinephrine <100 g/24 hr <156 jsg/24 hr
From Ref. 24.
' Values are mean I SD.
VMA = Vanillylmandelic acid: NMN = normetanephrine; MN =
metanephrine.
[451. Chromogranin A is a soluble protein contained in cate-
cholamine storage vesicles. Because it is released simulta-
neously with norepinephrine, its level in plasma reflects sym-
pathoadrenal activity [46]. But chromogranin A also is found in
blood of patients with other neuroendocrine tumors [47].
Because platelets concentrate catecholamines [481, patients
with pheochromocytoma have increased platelet norepineph-
rine and epinephrine content. Zweifler and Julius have sug-
gested that platelet catecholamine content might discriminate
between patients with pheochromocytoma and those with non-
pheochromocytoma-associated hypertension [49]. A recent
study showed, however, that the usefulness of platelet cate-
cholamines in diagnosing pheochromocytoma is limited be-
cause of the high false-positive rates—36% for platelet norepi-
nephrine and 19% for platelet epinephrine [50].
The simultaneous measurement of urinary norepinephrine
and 3,4-dihydroxyphenylglycol (DHPG) has been proposed as a
means of increasing the specificity of urine testing. Norepineph-
rifle that is released by neurons is again taken up and converted
to DHPG [511. Therefore, DHPG levels reflect the extent of
neuronal traffic. In patients with pheochromocytoma, however,
norepinephrine is released directly into the circulation and
results in higher ratios of norepinephrine/DHPG than observed
in other hypertensive patients [52]. Measuring free norepineph-
Table 3. Sensitivity and specificity of various biochemi
the diagnosis of pheochromocytoma
cal tests in
Reference Sensitivity
Biochemical test value1' (% ran ge)°
Specificity
(% range)°
Plasma NE + E >950 pg/mI 88--tOO
Urinary NMN + MN" >1.8 mg/24 hr 67--91
Urinary VMA" >11.0 mg/24 hr 28—56
93—101
83—103
98—102
From Ref. 24.
' Upper 95% confidence limits obtained from essential hypertension
subjects under basal conditions.
Values are expressed as 2 SE.d NE + E = norepinephrine plus epinephrine: NMN + MN =
normetanephrine plus metanephrine; VMA = vanillylmandelic acid.
rine in urine has been shown to be as accurate as the norepi-
nephrine/DHPG ratio, however [40].
Pharmacologic resting. The diagnostic dilemma in the work-
up of pheochromocytoma is how to separate patients with
pheochromocytoma and relatively low levels of synthetic activ-
ity from patients without pheochromocytoma who have second-
arily activated sympathetic nervous systems. Pharmacologic
tests are designed to either provoke secretion of catecholamines
by a pheochromocytoma or to suppress normal or excessive
activity of the sympathetic nervous system.
A provocative test usually is employed when the clinical
findings are highly suggestive of pheochromocytoma but plasma
catecholamine levels are less than 1000 pg/mI and the blood
pressure is only slightly increased (less than 160/100 mm Hg).
The glucagon stimulation test is widely used because it has few
side effects [53]. Glucagon is given as an intravenous bolus dose
of l.0 to 2.0 mg after determination of the patient's blood
pressure response to immersion of the hand in water at 4°C
(cold pressor test). A positive glucagon test requires a clear
increase (at least threefold, or over 2000 pg/mI, in plasma
catecholamines) 1 to 3 minutes after drug administration. A
simultaneous increase in blood pressure of at least 20/15 mm Hg
above the response to the cold pressor test strengthens the test
but is not necessary. If a rise in blood pressure is considered
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Fig. 6. Comparison of simultaneously measured indices of
catechola,nine production in 43 patients with surgically
con firmed pheochromocytoma. The vertical broken lines
represent the 95% upper confidence limits of values for
urinary vanillylmandelic acid (VMA) (i.e., II mg/24 hr) and
urinary metanephrines (MN) (i.e., 1.8 mg/24 hr) in 30
subjects with essential hypertension. NE + E denotes
norepinephrine plus epinephrine. Solid symbols denote
false-negative tests. (From Ref. 39.)
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Fig. 7. The clonidine suppression test in
pheochromocytoma. The cross-hatched area
represents the mean (218 pg/mi) and the 95% upper
confidence limits (500 pg/mI) of values obtained from
47 normal subjects. Values shown on the right of
each panel represent the lowest values reached (at
either 2 or 3 hours) after oral administration of 0.3
mg clonidine. (From Bravo EL: Adrenal medullary
function, in Diagnostic Endocrinology, edited by
Mooe WT, EASTMAN RC, Philadelphia, BC
Clon Decker, 1990, p 225.)
risky, the test can be performed with the patient receiving either
a calcium antagonist or an aipha-adrenergic blocking drug.
In patients with moderate increases in plasma catecholamines
(between 1000 and 2000 pg/mI), a suppression test should be
employed. The clonidine suppression test is based on the
capacity of clonidine, a centrally acting a2-adrenergic agonist,
to suppress the release of neurogenically mediated catechol-
amine release [54]. The test is based on the principle that
normal increases in plasma catecholamines are mediated
through activation of the sympathetic nervous system. In
patients with pheochromocytoma, however, the increases re-
sult from the diffusion of excess catecholamines from the tumor
into the circulation, bypassing the normal storage and release
mechanisms. Clonidine therefore should not suppress the re-
lease of catecholamines in patients with pheochromocytoma.
Figure 7 shows the results of the clonidine suppression test in
patients with proven pheochromocytoma [44]. The results were
compared with those of gender-matched and age-matched sub-
jects with essential hypertension. Of the 40 patients, 27 had
adrenal pheochromocytoma and 13 had extra-adrenal pheo-
chromocytoma. After clonidine was administered, plasma cat-
echolamine values fell below 500 pg/mi in all but one patient
with essential hypertension. In contrast, in all but one patient
with a pheochromocytoma, plasma catecholamine values re-
mained above 500 pg/mI after clonidine admiuistration. Accord-
ing to this experience, a normal clonidine suppression test
should consist of a fall in the values of plasma norepinephrine
plus epinephrine to a level below 500 pg/mI at 2 or 3 hours after
the oral administration of 0.3 mg of clonidine. It is important to
record blood pressure and heart rate responses and any effects
related to the central nervous system, because certain signs and
symptoms (such as drowsiness, thirst, and reductions in blood
pressure and heart rate) reflect the completeness of the gastro-
intestinal absorption of clonidine.
Hypotension is a potential hazard of the clonidine suppres-
sion test, but symptomatic hypotension is not a problem in the
untreated patient. All reported cases of severe hypotension
have occurred in patients who were receiving antihypertensive
medications or who had other conditions that would tend to
augment the effects of any antihypertensive agents [55, 56]. In
particular, the test should not be carried out in a patient with
marked volume depletion. In addition, administration of any
beta-adrenergic blocking agent should be discontinued approx-
imately 48 hours before the test is performed. Clonidine has a
potent vagotonic effect, so concomitant beta-adrenergic block-
ade could lead to marked bradycardia, further decreases in
stroke volume and cardiac output, and severe hypotension. In
addition, beta-adrenergic blockers can prevent the plasma-
catecholamine-lowering effect of clonidine in a patient without
pheochromocytoma because of the ability of such agents to
interfere with hepatic clearance of catecholamines [57].
Tumor localization. Tumor localization not only confirms the
diagnosis of pheochromocytoma but also assists the surgeon in
planning the surgical strategy. Advances in noninvasive imag-
ing techniques now provide a safe and reliable means of
localizing pheochromocytomas anywhere in the body. Com-
puted tomographic (CT) scanning is the most widely applied
and accepted modality for the anatomic localization of pheo-
chromocytoma [58]; it can accurately detect tumors larger than
1.0 cm. Because of its usual size, the tumor lends itself to
visualization in virtually every instance in which the tumor is in
the adrenal gland. Magnetic resonance imaging (MRI) is an
alternative and has several advantages over CT scanning [59].
First, it requires no radiation exposure. Second, MRI lends
itself to in-vivo tissue characterization; pheochromocytomas,
unlike other benign tumors that have a low signal intensity,
demonstrate a high signal intensity on T2-weighted image [59,
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Table 4. Accuracy of three imaging techniques in the
and diagnosis of pheochromocytomaa
localization
Parameter
CT MRI
(%) (%)
MIBG
(%)
Sensitivity
Specificity
pv ()h
PV (—)
98 100
70 67
69 83
98 100
78
100
100
87
a From Ref. 62.
b PV predictive value; based on a prevalance rate of 41% in this
highly selected group of patients.
60]. Third, MRI can differentiate tumor masses from surround-
ing vascular tissues, eliminating the need for the intravenous
administration of contrast material. It is the procedure of choice
in pregnant women because it poses no danger to the fetus, and
in patients with surgical clips, which interfere with CT. Scinti-
graphic localization with radioiodinated metaiodobenzylguani-
dine (MIBG) provides both anatomic and functional character-
ization of a tumor [61]. However, because this compound is
actively concentrated in sympathomedullary tissue through the
catecholamine pump, the administration of drugs that block the
reuptake mechanism (tricyclic antidepressants, guanethidine,
and labetalol) can give false-negative results. Phenoxybenz-
amine, prazosin, propranolol, and calcium antagonists do not
interfere with MIBG uptake.
A comparison of the three imaging techniques is shown in
Table 4. The data are from our prospective study involving 109
patients strongly suspected of having a pheochromocytoma
[62]. All the patients had CT scanning and MIBG scintigraphy;
40 patients with tumor masses had, in addition, an MRI as a
third localizing procedure. Forty-five patients had surgically
proven pheochromocytoma, 20 had non-pheochromocytoma
adrenal masses, and the remaining 44 were considered free of
the disease after repeated biochemical testing and long-term
followup. Based on the sensitivity, specificity, and predictive
value of each of the three imaging techniques, the following
sequence of localization is recommended. One should begin
with an abdominal CT (including the pelvic region) with special
attention to the adrenal gland. This is appropriate because 97%
of pheochromocytomas are located in the abdominal area and
90% are intra-adrenal. In patients with demonstrable tumors,
either MRI or MIBG scintigraphy should be performed next.
Even if a primary adrenal pheochromocytoma is identified,
MIBG can be useful in locating occult secondary or metastatic
sites; such sites are present in approximately 10% of cases.
Venous catheterization with selective sampling of blood for
measurement of plasma catecholamine concentration at various
sites along the superior and inferior vena cava is reserved for
patients whose clinical and biochemical tests strongly suggest
pheochromocytoma but in whom radiologic studies fail to
locate the tumor [63].
Treatment
The goals of medical therapy are the treatment or prevention
of cardiovascular complications and preparation of the patient
for surgical intervention. The most frequently used therapeutic
agent is phenoxybenzamine, a long-acting, non-competitive
alpha-adrenergic blocker. Typically, treatment is initiated at 20
mg/day and increased stepwise to 80—100 mg/day as tolerated
according to the severity of postural signs and symptoms (that
is, hypotension, tachycardia, syncope, dizziness). Prazosin
hydrochloride, a shorter-acting alpha-blocking agent, also has
been used with some success [64]. Calcium antagonists are
attractive agents because they are not only effective in control-
ling blood pressure, but they also are useful in managing
cardiovascular complications [65]. They attenuate the pressor
response to norepinephrine and can prevent catecholamine-
induced coronary spasm and myocarditis. In addition, calcium
antagonists have none of the complications associated with
chronic use of alpha-adrenergic blockers. Beta-adrenergic
blockers are added as needed to control tachycardia and
arrhythmias. If beta blockade is absolutely contraindicated,
either lidocaine or amiodarone can be used for serious rhythm
disturbances [66]. Hypertensive crises can be managed with the
parenteral administration of either phentolamine hydrochloride
or sodium nitroprusside. Nicardipine, infused continuously at a
rate of 2.5 to 7.5 zg/kg/min, prevents the severe hypertensive
crises that usually occur during tumor manipulation at surgery,
despite 3- to 85-fold increases in ciirculating catecholamines
[67].
Before surgery, every attempt must be made to minimize the
possibility of intraoperative severe hypertension consequent to
catecholamine release. The best drug for this purpose is phe-
noxybenzamine. Its theoretical advantages relate to its ability
to permit vascular volume repletion and to block alpha recep-
tors non-competitively, making it difficult for catecholamines
released during surgery to overcome the drug's blocking effect
[68, 69]. Conventional wisdom dictates that blood pressure
should be controlled with phenoxybenzamine for at least 4
weeks before the surgical procedure. The stringent criteria
proposed for ensuring adequate preoperative preparation with
alpha blockade are: (I) arterial pressure not greater than 160/90
mm Hg for 48 hours; (2) orthostatic hypotension present but not
exceeding 80/45 mm Hg; (3) electrocardiogram free of ST-
segment or T-wave changes for at least 2 weeks; and (4) no
more than one premature ventricular contraction every 5 min-
utes [701.
However, a recent review of 60 of our patients with pheo-
chromocytoma who underwent 63 surgical procedures dis-
closed that consistently successful surgical outcomes can be
achieved without profound and prolonged aipha-adrenergic
blockade preoperatively [71]. Of 29 patients who did not receive
alpha-adrenergic blockade, there were no deaths or cerebral or
cardiac complications. In addition, 80% of the patients required
neither vasopressors nor vasodilators in the immediate postop-
erative period. Further, there were no differences in the length
of stay in the postoperative acute care unit or in the duration of
postoperative hospitalization between patients who received
alpha blockers and those who did not. These favorable out-
comes reflect the recent advances in anesthetic and monitoring
techniques and the availability of fast-acting drugs capable of
correcting sudden hemodynamic abnormalities.
Some postoperative complications require emphasis. The
first is hypotension, which results from marked arterial and
venous dilation consequent to the withdrawal of catechol-
amines and to the presence of diminished receptor sensitivity to
endogenous catecholamines. Hypotension can be compounded
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by previous postoperative alpha blockade and inadequate vol-
ume repletion; volume replacement, rather than vasopressors,
is the primary treatment. Second, persistence of hypertension
beyond 14 days after tumor excision should raise concern about
residual or metastatic pheochromocytoma. If plasma catechol-
amines are still elevated at this time, the administration of
clonidine (0.3 mg orally) will determine whether the hyperten-
sion is neurogenically mediated. Third. hypoglycemia can de-
velop postoperatively because of excessive release of insulin
previously inhibited by high levels of circulating catechol-
amines [721. In some instances, hypoglycemia can manifest as
persistent hypotension resistant to pressor agents and volume
repletion.
Malignant pheochromocyronia
Malignant pheochromocytomas are, in general, slow-growing
tumors. Evidence of malignancy can occur years after success-
ful surgical excision of an apparently benign pheochromocy-
toma (median 5.6 years) [731. The 5-year survival for patients
with malignant pheochromocytoma is approximately 44%, but
some patients have survived for 20 years or longer [731. These
tumors respond poorly to chemotherapy and to radiotherapy.
The first goal of treatment is counteracting the effects of
increased circulating catecholamines with alpha- or beta-adren-
ergic blocking drugs and/or calcium antagonists. The second is
decreasing catecholamine synthesis by the tumor with alpha-
methyltyrosine, a "false" catecholamine precursor that inhibits
the rate-limiting enzyme in catecholamine synthesis, tyrosine
hydroxylase [74]. Whenever possible, surgical excision or de-
hulking of accessible tumors should be performed. This maneu-
ver often helps decrease the levels of circulating catechol-
amines and provides easier control of blood pressure and other
manifestations. Combination chemotherapy with cyclophos-
phamide, vincristine, and dacarbazine has been used in patients
with advanced malignancy and is effective in suppressing the
activity of some tumors [75]. However, the effect is only
temporary. The administration of 311-MIBG to ablate primary
and metastatic sites has been used with some success, with
remissions and palliation having been reported [76—78]. How-
ever, initial therapeutic responses have not produced significant
long-lasting benefit even with repeated administration [79].
Questions and answers
DR. JOHN T. HARRINGTON (Chief of Medicine, Neit'ton-
Wellesley Hospital, Newton, Massachusetts): In the slides you
showed on clinically unsuspected pheochromocytoma, it ap-
pears that approximately one-third of the pheos showed up only
at postmortem; that is, a high percentage were unsuspected
during life. Does that mean that they were endocrinologically
active but were missed, or were those tumors not endocrino-
logically active at all?
DR. BRAVO: The patients reported in the five articles were
described as dying of cardiovascular complications usually
associated with chronic hypertension. This indicates to me that
the tumors were functional but that the diagnosis was not
suspected before death.
DR. HARRINGTON: You briefly alluded to studies of receptor
assays in animals that had been treated with norepinephrine and
epinephrine. Have any studies examined receptors in patients?
Is there a way of doing such studies after a pheochromocytoma
has been removed? What kind of down-regulation helps ac-
count for the 15% of patients who are normotensive?
DR. BRAVO: One study reported that catecholamine resis-
tance in fat cells from pheochromocytomas might be due to (1)
the formation of a hormone antagonist, which modulates the
cellular response to continuous stimulation by catecholamines
or (2) an adaptive increase in phosphodiesterase activity, which
modulates cellular sensitivity [801. In another study, Greenacre
and Conolly found marked depression of lymphocytic beta-
adrenoreceptor responsiveness in 4 patients with proven pheo-
chromocytoma [81]. The clinical relevance of such findings to
the pheochromocytoma patients with normal pressure despite
having high circulating catecholamines remains to be estab-
lished.
DR. NIcOLA0s E. MADIAS (Chief Division of Nephrology,
New England Medical Center, Boston, Massachusetts): I was
impressed with the high sensitivity and specificity of the symp-
tomatic triad of sweating attacks, tachycardia, and headache in
a hypertensive patient in diagnosing pheochromocytoma as
reported in a French study you cited [2]. I was wondering how
rigorously the diagnosis of pheochromocytoma was pursued in
that study that allowed the authors to arrive at those sensitivity
and specificity rates?
DR. BRAVO: In that particular study [2], the investigators
screened 2585 hypertensive patients for pheochromocytoma by
recording the symptoms known to be those most associated
with the disease, that is, headaches, palpitations, and sweating
attacks. Only 6.5% (168 patients) reported all three symptoms;
72.4% of the entire patient population reported one or another
of these complaints. Of the(168) patients who reported all three
symptoms, 5,9% (10 patients) had pheochromocytoma. The
24-hour urinary VMA was the sole confirmatory test used in
this study. Urinary VMA has poor sensitivity, so it is possible
that some pheochromocytoma patients without the triad were
missed.
DR. MADIAS: Are there any known differences in the biology
of tumors in patients who have sustained, as opposed to
episodic, hypertension?
DR. BRAVO: Norepinephrine-secreting tumors usually are
associated with sustained hypertension. Tumors that secrete
relatively large amounts of epinephrine together with norepi-
nephrine are associated with episodic hypertension. Pure epi-
nephrine-secreting tumors can produce hypotension rather than
hypertension. Large (>50 g) cystic pheochromocytomas often
are asymptomatic because the secreted catecholamines are
metabolized within the tumor, and therefore only a small
amount, if any, of free catecholamines is released into the
circulation. However, sudden catecholamine release, either
spontaneous or provoked, can occur in these tumors and cause
marked hypertension in an otherwise-normotensive patient.
Small tumors ( 50 g) have a high metabolic turnover rate and
release free catecholamines into the circulation, producing
persistent signs and symptoms.
DR. MICHAEL MONAHAN (Fellow in Nephrology, New En-
gland Medical Center): Do you think the increased use of
ambulatory blood pressure monitoring will help identify pa-
tients who have unsuspected pheochromocytoma by finding
labile hypertension?
DR. BRAVO: I doubt it very much. Labile hypertension is so
common that one would end up with very high false-positive
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rates. The cost, time, effort, and low yield do not justify the use
of ambulatory blood pressure monitoring to screen patients.
DR. MONAHAN: A group from Scotland described the use of
a clonidine suppression test that measured urinary catechol-
amines in an overnight sample [821, but I haven't seen a
followup on that test. Would this test add any diagnostic
information to a serum clonidine suppression test?
DR. BRAVO: Neurogenic tone is normally reduced at night.
The administration of clonidine at night might further suppress
any remaining neurogenic activity. Thus, one might differen-
tiate more reliably patients with pheochromocytoma from other
hypertensives with increased neurogenic activity. The study
you allude to reported that the test identified all 12 patients in
whom pheochromocytoma was present. It is uncertain what
diagnostic information this test adds to the standard clonidine
suppression test, as the two tests were not directly compared in
the same patient population. A major drawback of the test is
that it requires hospitalization with carefully timed collection of
urine samples.
DR. MADJAS: I would like to return to an earlier question.
You have a referred population that has been subjected to an
exhaustive workup for the diagnosis of pheochromocytoma.
You should be able to derive from that population the sensitiv-
ity and specificity of combinations of clinical symptoms in
diagnosing pheochromocytoma. Have you carried out this
exercise? If so, how does your experience compare with the
results of the French study you cited?
DR. BRAVO: Our patients were referred to us because of signs
and symptoms strongly suggestive of pheochromocytoma. In
this highly selected group, the prevalence rate of the disease
was about 41%; thus, signs and symptoms alone were poor
predictors of the presence of pheochromocytoma in this group.
I have no idea how common the triad (of headaches, sweating
attacks, and tachycardia) was in our patients. We haven't yet
extracted that information from the charts. It will be interesting
to find out.
DR. HARRINGTON: You mentioned that some of your patients
had orthostatic hypotension. If I understood you correctly,
tilt-table testing was not able to detect differences between
those susceptible to hypotension and those not susceptible. My
question is, were there any differences in norepinephrine or
epinephrine blood levels between these two populations? If not,
what's your speculation for the difference?
DR. BRAVO: There are no differences in the type of catechol-
amine secreted between patients susceptible to postural hypo-
tension and those who are not. Neither are there any significant
differences in intravascular volume or basal hemodynamic
characteristics. Patients susceptible to postural hypotension
are unable to increase their peripheral vascular resistance in
response to head-up tilt. It is unclear why some patients have
this hemodynamic abnormality and some do not. It would be
interesting to determine whether tumor removal corrects this
hemodynamic abnormality.
DR. MADIAS: In view of the "catecholamine hypothesis" for
the pathogenesis of left-ventricular hypertrophy, do patients
with pheochromocytoma express inordinate rates of echocar-
diographically diagnosed left-ventricular hypertrophy?
DR. BRAVO: As I mentioned, the prevalence of left-ventricu-
lar hypertrophy is no higher in patients with pheochromocy-
toma than in patients with essential hypertension despite ten-
fold higher plasma catecholamine values in the former.
DR. HARRINGTON: Excluding patients with the MEA syn-
drome, do we know anything about what makes an individual
more likely to develop a pheochromocytoma?
DR. BRAVO: No information is available on sporadic pheo-
chromocytoma.
DR. HARRINGTON: Are there any HLA linkages with pheo-
chromocytoma, or are we still in the dark?
DR. BRAVO: No HLA linkages have been reported.
DR. RONALD PERRONE (Division of Nephrology, New En-
gland Medical Center): In view of the differential effect of
alpha- and beta-receptor stimulation on potassium movement
into cells, do you find that plasma potassium correlates with the
output of the tumor? Is it useful in any way?
DR. BRAVO: The acute systemic administration of epineph-
rine decreases extracellular potassium by shifting potassium
intracellularly. Therefore, it has been postulated that pheochro-
mocytoma patients might exhibit hypokalernia. However, in
our experience it is rare to see hypokalemia in these patients,
even in those with predominant epinephrine-secreting tumors.
When it does occur, it usually is associated with secondary
aldosteronism.
DR. HARRINGTON: As an inveterate potassium skeptic. I'm
delighted to hear that!
DR. PAUL KURTIN (Director, Dialysis Unit, Division of
Nephrologv, New England Medical Center): In terms of the
glucagon stimulation test, are there any practical things we
should know'? Should we be aware of any side effects when we
administer the glucagon?
DR. BRAVO: The most important side effect associated with
the glucagon stimulation test is the rapid rise in blood pressure,
which is readily counteracted with phentolamine. Alternatively,
the rise in blood pressure can be prevented by the administra-
tion of oral nifedipine 30 minutes before testing.
DR. MADIAS: We reported a patient with pheochromocytoma
in whom severe lactic acidosis fealured prominently in the
clinical presentation [831. High concentrations of epinephrine
and norepinephrine have the potential for generating substantial
hyperlactatemia on the basis of their metabolic and vasocon-
strictor effects: both these influences result in overproduction
and underutilization of lactate.
DR. BRAVO: Severe lactic acidosis is an uncommon manifes-
tation of pheochromocytoma, but it is a potential complication
in patients with severe peripheral vasoconstriction.
DR. ALAN MURRAY (Fellow in Nephrologv, New England
Medical Center): What approach do you advise for the evalu-
ation of the asymptomatic adrenal mass identified by CT scan or
MRI'?
DR. BRAVO: All patients with incidental adrenal adenomas
should have a thorough clinical evaluation to rule out malig-
nancy and to determine whether the mass is functional. Param-
eters used to reach a therapeutic decision include: (I) tumor
extent and size on CT, (2) hormonal assessment, and (3) MRI.
I recommend the following guidelines: (I) Tumors should be
resected if they are larger than 6.0 cm in diameter, if they are
functional, or even if they are less than 6.0 cm diameter and
nonfunctional but have an MRI T, signal intensity greater than
3.0 (adrenal versus liver). (2) Nonfunctional tumors less than
6.0 cm in diameter but which have an MRI T2 signal intensity
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greater than 1.4 but less than 3.0 should have cytologic aspira-
tion before one decides on resection, (3) Nonfunctional tumors
less than 6.0cm in diameter with an MRI T2 signal intensity less
than or equal to 1.4 should have studies yearly and should be
resected if they grow by 1.0 cm/year.
DR. KURTIN: Would you please elaborate on the relationship
between the size of the tumor and symptoms, whether cystic
tumors are more or less symptomatic compared with solid, and
the relationship among patient age, tumor size, and symptoms?
DR. BRAVO: Small tumors (< 50 g) produce more symptoms
than do large tumors (> 50 g). Children are more prone to
develop dilated cardiomyopathy, have fewer malignant tumors
and more extra-adrenal tumors, have greater bilaterality and
multiplicity of tumors, and to have an increased incidence of
multiple endocrine neoplasia and familial disease. Elderly sub-
jects (> 65 years) have less pronounced clinical manifestations,
perhaps because of decreased beta-adrenergic responsiveness
associated with aging.
DR. GEETHA NARAYAN (Division of Nephrology, St. Eliza-
beth's Hospital of Boston, Brighton, Massachusetts): Is a level
of plasma catecholamines that is greater than or equal to 2000
pg/mi diagnostic even when obtained as a random drawing, or
only when it is obtained under carefully controlled conditions as
generally recommended, that is, with the patient resting in a
quiet room with an indwelling venous catheter for a few minutes
before drawing the sample?
DR. Bivo: Any plasma catecholamine value that is obtained
under less than optimal, standardized conditions has very little
clinical utility. It is important that one record the blood pressure
at the time of blood sampling because if the plasma catechoi-
amine level is less than 1000 pg/mI and the patient is markedly
hypertensive, the diagnosis of pheochromocytoma is not likely.
On the other hand, a plasma catecholamine level of 1000 pg/mi
or less in the presence of a normal blood pressure does not rule
out the disorder. As previously shown, however, blood pres-
sure can be normal despite high circulating catecholamine
levels in active pheochromocytoma.
Reprint requests to Dr. E. Bravo, Department of Heart and Hvper-
tension, Cleveland Clinic Foundation, One Clinic Center, 9500 Euclid
Avenue, Cleveland, Ohio 44194, USA
References
I. THOMAS JE, ROOKE ED, KVALE WF: The neurologist's experience
with pheochromocytoma: A review of 100 cases. JAMA 197:754—
758, 1966
2. PLOUIN PF, DEGOULET P, TUGAYE A, DUCROCQ MB, MENARD J:
Screening for pheochromocytoma: A semilogical study of 2585
patients including II patients with pheochromocytoma. Noui'
Presse Med 10:869—872, 1981
3. LANDSBERG L, YOUNG JB: Catecholamines and the adrenal me-
dulla, in Williams' Textbook ofEndocrinology, edited by WILSON
JD, FOSTER DW. Philadephia, Saunders, 1985, pp 891—965
4. HEATH H, EDIS AJ: Pheochromocytoma associated with hypercal-
cemia and ectopic secretion of calcitonin. Ann Intern Med 91:208—
210, 1979
5. FISHER BM, MACPuCE GJ, DAVIS DL, MCPHERSON SG, BROWN
IL, GOLDBERG A: A case of watery diarrhea syndrome due to an
adrenal pheochromocytoma secreting vasoactive intestinal peptide
with coincidental autoimmune thyroid disease. Aria Endocrinol
(Copenh) 114:340—344. 1987
6. SACKEL SG, MANSON JE, HARAW Si, BURAKOFE R: Watery
diarrhea syndrome due to an adrenal pheochromocytoma secreting
vasoactive intestinal peptide. Dig Dis Sci 30:1201—1207, 1985
7. FORMAN BH, MARBAN F, KAYNE RD, PASSARELLI NM, BOBROW
SN, LIv0LSI VA, MERINO M, MINOR M, FARBER LR: Ectopic
ACTH syndrome due to pheochromocytoma. Yale J Biol Med
82:181—189, 1979
8. BEASER RS, GUAY AT, LEE AK, SILVERMAN ML, FLINT LD: An
adrenocorticotropic hormone-producing pheochromocytoma: Di-
agnostic and immunohistochemical studies. J Urol 135:10—13, 1986
9. Jsso' DS, CUNNAH D, MILLER JGB. NEVILLE E, COATES P,
D0NIACH 1, BESSER GM, REES LH: A pheochromocytoma present-
ing with Cushing's syndrome associated with increased concentra-
tions of circulating corticotropin releasing factor. J Endocrinol
113:133—138. 1987
10. JONES DJ, DURING P: Phaeochromoyctoma presenting as an acute
abdomen: Report of two cases. Br Med J 291:1267—1268, 1985
11. GROSSMAN E, KNECHT A, HOLTZMAN E, NUSSINOVICH N,
ROSENTHAL T: Uncommon presentation of pheochromocytoma:
Case studies. Angiology 36:759—765, 1985
12. ROSATI LA. AUGUR NA JR: lschemic enterocolitis in pheochromo-
cytoma. Gastroenterology 60:581—585, 1971
13. DELANEY JP, PARTZKY AZ: Necrosis of a pheochromocytoma with
shock. NEngIJ Med 280:1394—1395. 1969
14. PRIMHAK RA, SPICER RD, VARIEND S: Sudden death after minor
abdominal trauma: An unusual presentation of phaeochromocy-
toma. Br Med J 292:95—96, 1986
IS. STENSTROM G, SJOSTROM K, SMITH U: Diabetes mellitus in
phaeochromocytoma. Fasting blood glucose levels before and after
surgery in 60 patients with phaeochromocytoma. Ada Endocrinol
106:511—515, 1984
16. BORNEMANN M, HILL SC. KIDD GG: Lactic acidosis in pheochro-
mocytoma. Ann Intern Med 105:880—882, 1986
17. VAN VLIET PD, BURCHEL MB, TITUS JL: Focal myocarditis
associated with pheochromocytoma. N Engl J Med 274:1102—1108,
1966
18. CHENG TO, BASHOUR TT: Striking electrocardiographic changes
associated with pheochromocytoma. Chest 70:397—399, 1976
19. COHEN CD, DENT DM: Pheochromocytoina and acute cardiovas-
cular death (with special reference to myocardial infarction). Post-
gi'ad Med J 60:111—115, 1984
20. DE LEEUW PW, WALTMAN FL, BIRKENHAGER WH: Noncardio-
genie pulmonary edema as the sole manifestation of pheochromo-
cytoma. Hvpe;'tension 8:810—812, 1986
21. ACHONG MR. KEANE PM: Pheochromocytoma unmasked by desi-
pramine therapy. Ann Intern Med 94:358—359, 1981
22. AGABITI-R0SEI E, ALICANDRI Ci, COREA I: Hypertensive crises in
patients with pheochromocytoma given metoclopramide. Lance!
1:600, 1977
23. BouLoux PMG. GROSSMAN A, BESSER GM: Naloxone provokes
catecholamine release in pheochromocytomas and paragangliomas.
C/in Endocrinol 24:319—325, 1986
24. BRAVO EL: The syndrome of primary aldosteronism and pheochro-
mocytoma, in Diseases of the Kidney (4th ed, vol II), edited by
SCI-1RIER RW, GOTTSCHALK CW, Boston, Little, Brown, 1988, p
1642
25. ST. JOHN SUTTON MG, SIiEF'S SG, LIE iT: Prevalence of clinically
unsuspected pheochromocytoma: Review of a 50-year autopsy
series. Mayo Clin Proc 56:354—360, 1981
26. HARTLEY L, PERRY-KEENE D: Phaeochromocytoma in Queens-
land: 1970—83. Aust NZJ Surg 55:471—475. 1985
27. STENSTROM G, SVARDSUDD K: Pheochromocytoma in Sweden
1958—1981: An analysis of the National Cancer Registry Data. Aria
Med Stand 220:225—232, 1986
28. KRANE NK: Clinically unsuspected pheochromocytoma: Experi-
ence at Henry Ford Hospital and a review of the literature. Arch
Intern Med 146:54—57, 1986
29. VAN HEERDEN JA, SHEPS SO, HAMBERGER B, SHEEDY PF,
POSTON JG. REMINE WH: Pheochromocytoma: Current status and
changing trends. Surgery 91:367—373. 1982
30. BRAVO EL, TARAZI RC, GIFEORD RW JR. STEWART BH: Circulat-
ing and urinary catecholamines in pheochromocytoma. N EngI J
Med 301:682—686, 1979
Nephrology Forum: Pheochromocvto,na 555
31. TARAZI RC, DUSTAN HP, FROHLICH ED, GIFF0RD RW JR, HOFF-
MAN GC: Plasma volume and chronic hypertension. Arch Intern
Med 125:835—842, 1970
32. T5uJIM0T0 G, HONDA K, HOFFMAN BB, HASHIMOTO K: Desen-
sitization of postjunctional a1- and a,-adrenergic receptor-mediated
vasopressor responses in rat harboring pheochromocytonia. Circ
Res6l:86—98, 1987
33. Bi.&vo EL, TARAZI RC, FOUAD FM, TEXTOR SC, GIFFORD RW
JR: Blood pressure regulation in pheochroniocytoma. Hypertension
4 (suppl 1I):11193—11199, 1982
34. PROKOCIMER PG, MAZE M, HOFFMAN BB: Role of the sympathetic
nervous system in the maintenance of hypertension in rats harbor-
ing pheochromocytoma. J Pharmaco/ Exp Therap 241:870—874,
1987
35. BRAVO EL, FOUAD-TARAZI F, Rossi G. IMAMURA M, LIN WW,
MADKOUR MA, WICKER P, CRESSMAN M, SARAGOCA M: A reeval-
uation of the hemodynamics of pheochromocytoma. Hypertension
15 (suppl 1):!128—1131, 1990
36. LEVENSON JA, SAFAR ME, LONDON GM, SIMON AC: Hemody-
namics in patients with pheochromocytoma. C/in Sci 58:349—356,
1980
37. LAKS MM, MORADY F, SWAN HJC: Myocardial hypertrophy
produced by chronic infusion of sub-hypertensive doses of norep-
inephrine in the dog. Chest 64:75—78, 1973
38. SnUB C, CUETO-GARCIA L, SI-iEPs SG, IL5TRUP DM, TAJIK AJ:
Echocardiographic findings in pheochromocytoma. Am J Cardiol
57:971—975, 1986
39. BRAVO EL, GIFFORD RW JR: Pheochromocytoma: Diagnosis,
localization and management. N Engi J Med 311:1298—1303, 1984
40. DUNCAN MW, COMPTON P, LAZARUS L, SMYTHE GA: Measure-
mentofnorepinephrine and 3,4-dihydroxyphenylglycol in urine and
plasma for the diagnosis of pheochromocytoma. N Eng! J Med
319:136—142, 1988
41. BAINES AD, CRAAN AA, CHAN W, MORGUNOV N: Tubular secre-
tion and metabolism of dopamine, norepinephrine. methoxy-
tryamine and normetanephrine by the rat kidney. J P/iarinacol Exp
Ther 208:144—147, 1979
42. JARROTT B. LOUIS Wi: Abnormalities in enzymes involved in
catecholamine synthesis and catabolism in pheochromocytoma.
C/in Sci Mo! Med 53:529—535, 1977
43. CROUT JR. SJOERDSMAA: Turnover and metabolism of catechol-
amine in patients with pheochroniocytoma. J C/in lutes! 43:94,
1964
44. BRAVO EL: Adrenal medullary function, in Diagnostic Endocrino!-
ogy, edited by MOORE WT. EASTMAN RC, Philadelphia, Toronto,
B.C. Decker, Inc., 1990, pp 217—226
45. O'CONNOR DT, DEFTOS U: Secretion of chromogranin A by
peptide producing endocrine neoplasms. N EngIJ Med 314:l145—
1151, 1986
46. WEINSHILBAUM RM: Serum dopamine /3-hydroxylase. Phar,naco/
Rev 30:133—166, 1979
47. SOBOL RE, MEMOLI V, DEFTOS Li: Hormone-negative, chromo-
granin A-positive endocrine tumors. N Engi J Med 320:444—447,
1989
48. ABRAMS WB, SOLOMON HM: The human platelet as a pharmaco-
logic model for the adrenergic neurone: The uptake and release of
norepinephrine. C/in Pharmacol Ther 10:702—709, 1969
49. ZWEIFLER AJ, JULIUS 5: Increased platelet catecholamine content
in pheochromocytoma. N Engi J Med 306:890—894,1982
50. BERENT H, UCHMAN B, WOCIAL B: Platelet norepinephrine and
epinephrine concentration in patients with pheochromocytoma. Am
JHypertens 3:618—621, 1990
SI. GOLDSTEIN DS, EISENHOFER G, STULL R, FOLIO Ci, KEISER HR.
KOPIN tJ: Plasma dihydroxyphenylglycol and the intraneuronal
disposition of norepinephrine in humans. J C/in invest 82:213—220,
1988
52. BROWN MJ: Simultaneous assay of noradrenaline and its deami-
nated metabolite, dihydroxyphenylglycol, in plasma: Simplified
approach to the exclusion of phaeochromocytoma in patients with
borderline elevation of plasma noradrenaline concentration. Etir J
C/in Invest 14:67—72, 1984
53. LAWRENCE AM: Glucagon provocative test for pheochromocy-
toma. Ann Intern Med 66:1091—1096, 1967
54. BRAVO EL, TARAZI RC, FOUAD FM, \/IDT DG, GIFFORD RW JR:
Clonidine-suppression: A useful aid in the diagnosis of pheochro-
mocytoma. N Eng/ J Med 305:623—626, 1981
55. BURRIS IF, D'ANGELO U: Complications of clonidine suppression
test for pheochromocytoma. N Eng! J Med 307:756—757, 1982
56. GIVEN BD, TAYLOR T, LILY US, DZAU VJ: Symptomatic hypoten-
sion following clonidine suppression test for pheochromocytoma.
Arch intern Med 143:2195—2196, 1983
57. ESLER M. JACKMAN G, LEONARD P, SKEWS H, BOBIK A, JENNINGS
G: Effect of propranolol on noradrenaline kinetics in patients with
essential hypertension. Br] C/in Phurmaco! 12:375—380, 1981
58. GLAZER GM, FRANCIS IR, QUINT LE: Imaging of the adrenal
glands. Invest Radio! 23:3—Il, 1988
59. FINK Ii, REINING JW, DWYER AJ, DOPPMAN IL, LINEI-IAN WM,
KEISER HR: MR imaging of pheochromocytoma. J Comput Assist
Tomogr 9:454—458. 1985
60. DOPPMAN JL, REINING 1W, DWYER AJ, FRANK JP, NORTON 1,
L0RLAUx DL, KEISER HR: Differentiation of adrenal masses by
magnetic resonance imaging. Surgery 102:1018—1026, 1987
61. SISS0N JC, FRAGER MS, VALK TW, GROSS MD, SWANSON DP,
WIELAND DM, TOBES MC, BEIERWALTES WH, THOMPSON NW:
Scintigraphic localization of pheochromocytoma. N Eng! J Med
305:12—17, 1981
62. BRAVO EL, SAHA G. Go R: Preoperative localization of pheochro-
mocytoma: A prospective comparison of '311-Metaiodobenzylguan-
idine and abdominal computed tomography (abstract). Prog Fourth
Fur Mtg 1-lypertens, Milan, Italy, June 1989
63. ALLISON Di. BROWN MJ, JONES DH, TIMMIS JB: Role of venous
sampling in locating a pheochromocytoma. Br Med J 286:1122—
1124. 1983
64. NICHOLSON JP, VAUGHN ED JR, PICKERING TG, RESNICK LM,
ARTUSIO J, KLEINERT HD, LOPEZ-OVERJERO JA, LARAGH JH:
Pheochromocytoma and prazosin. Ann Intern Med 99:477—479,
1983
65. SERFAS D, SHOBACK DM, LORELL BH: Pheochromocytoma and
hypertrophic cardiomyopathy: Apparent Suppression of symptoms
and noradrenaline secretion by calcium-channel blockade. Lancet
2:711—713, 1983
66. SOLARES G, RAMOS F, MARTIN-DURAN R, SAN-JOSE JM, BUI-
TRAGO M: Amiodarone, phaeochromocytoma and cardiomyopathy.
Anaesthesia 41:186—190, 1986
67. PROYE C, THEVENIN D, CECAT P, PETILLOT P, CARNAILLE B,
VERIN P. SAUTIER M, RACADOT N: Exclusive use of calcium
channel blockers in preoperative and intraoperative control of
pheochromocytomas: Hemodynamics and free catecholamine as-
says in ten consecutive patients. Surgery 106(6): 1149—1154. 1989
68. STENSTROM G, HAUAMAE H, TISSELL LE: Influence of pre-
operative treatment with phenoxybenzamine on the incidence of
adverse cardiovascular reactions during anesthesia and surgery of
phaeochromocytoma. Acta Anaesthesio/ Scand 29:797—803, 1985
69. HOFFMAN BB, LEFKOWITZ Ri: Adrenergic receptor antagonists, in
The Pharmacologic Basis of Therapeutics, edited by GILMAN AG,
GOODMAN LS. RALL TW, NIES AA, TAYLOR P, New York,
Macmillan, 1990, pp 221—243
70. DESMONTS JM, MARTY I: An anesthetic management of patients
with pheochromocytoma. Br] Anecth 56:781—789, 1984
71. BOUTR05 AR, BRAVO EU, ZANETTIN (i, STRAFFON RA: Perioper-
ative management of 63 patients with pheochromocytoma. C/eve
C/in J Med 57:613—617,1990
72. CHAMBERS S. ESPINER EA. DONALD RA, NICHOLLS MG: Hypo-
glycemia following removal of phaeochromocytoma: Case report
and review of the literature. Postgrad flied J 58:503—506, 1982
73. REMINE WH, CHONG GC, VAN HEERDEN IA, SHEPS SG, HARRI-
SON EG JR: Current management of pheochromocytoma. Ann Surg
179:740—748, 1974
74. JONES NF. WALKER G, RUTHVEN CRJ. SANDLER M: a-Methyl-p-
tyrosine in the management of pheochromocytoma. Lancet 2:1105—
1109. 1968
75. AVERBUCH SD, STEAKLEY CS, YOUNG RC, GELMANN EP, GOLD-
STEIN DS. STULL R, KEISER HR: Malignant pheochromocytoma:
Effective treatment with a combination of cyclophosphamide,
vincristine, and dacarbazine. Ann Intern Med 109:267—273, 1988
556 Nephrologv Forum: Pheochromocvrnma
76. SissoN JC, SHAPIRO B, BEIERWALTES WI-I, GLOWNIAK IV, NA-
KAJO M, MANGNER TJ, CAREY JE, SWANSON DP, Co JE,
SATTERLEE WG, WIELAND DM: Radiopharmaceutical treatment of
malignant pheochromocytoma. J Nuci Med 25:197—206, 1984
77. VOOTE PA, HOEFNAGEL CA, IDE KRAKER J: Radionuclide therapy
of neural crest tumors. Med Pediatr Oncol 15:192—195, 1987
78. GONCALVES E, NJNANE I, WESE FX, LEONET J, PIRET L, CORN U
U, DE MEYER R: Familial pheochromocytoma: successful treat-
ment with '311-MIBG. Med Pediatr Oncol 18(2): 126—130, 1990
79. SHEP5 SU, JIANG NS, KLLEE GO, VAN HEERDEN JA: Recent
developments in the diagnosis and treatment of pheochromocy-
toma. Mayo C/in Proc 65:88—95, 1990
80. SMITH U, SJOSTROM L, STENSTROM 0, ISAKSSON 0, JACOBSSON B:
Studies on the catecholamine resistance in fat cells from patients
with pheochromocytoma. Eur J C/in Invest 7:355—361, 1977
81. GREENACRE 1K, CONOLLY ME: Desensitization of the /3-adrenore-
ceptor of lymphocytes from normal subjects and patients with
pheochromocytoma: Studies in vivo. Br J C/in Pharmacol 5:191—
197, 1978
82. MACDOUGALL IC, ISLES CG, STEWART H, ET AL: Overnight
clonidine suppression test in the diagnosis and the exclusion of
pheochromocytoma. Am J Med 84:993—1000, 1988
83. MADIAS NE, G0ORN0 WE, HERSON S: Severe lactic acidosis as a
presenting feature of pheochromocytoma. Am J Kidney Dis 10:250—
253, 1987
